Oral Immunoglobulin Levels are Not a Good Surrogate for Cervical Immunoglobulin Levels
Open Access
- 1 January 2012
- journal article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 2, 61
- https://doi.org/10.3389/fonc.2012.00061
Abstract
Background: We sought to determine whether oral secretions could be used as a surrogate for cervical secretions for monitoring cervical immunoglobulin (Ig) levels. To do so, we examined (1) whether oral IgG and IgA levels correlated with those observed at the cervix, and (2) whether time of menstrual cycle and other factors previously reported to influence cervical Ig levels were associated with oral IgG and IgA levels. Methods: We obtained oral samples from a group of 85 Costa Rican woman 25–35 years of age measured at three time points during one menstrual cycle. Total IgG and IgA levels were measured by ELISA. Generalized estimating equations methods that account for repeated measures were used to evaluate the association between oral and cervical Ig levels and to evaluate the association between various covariates and oral IgA and IgG levels. Results: We did not observe an association between oral and cervical IgG [linear regression coefficient (LRC) 0.01; 95% CI, −0.05 to 0.07] and IgA levels (LRC 0.02; 95% CI, −0.04 to 0.08). Oral IgG and IgA levels were not influenced by phase of menstrual cycle, in contrast to what has previously been observed for cervical Ig levels. Conclusion: Our data suggest that oral IgG and IgA measures are not a good surrogate for cervical IgG and IgA levels. Future studies should examine whether antigen-specific antibody responses induced by vaccination correlate across mucosal sites.Keywords
This publication has 16 references indexed in Scilit:
- Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young womenThe Lancet, 2009
- Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trialThe Lancet, 2009
- Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated womenVaccine, 2008
- Specific Antibody Levels at the Cervix During the Menstrual Cycle of Women Vaccinated With Human Papillomavirus 16 Virus-Like ParticlesJNCI Journal of the National Cancer Institute, 2003
- Mucosal Vaccination Strategies for WomenThe Journal of Infectious Diseases, 1999
- Design and methods of a population-based natural history study of cervical neoplasia in a rural province of Costa Rica: the Guanacaste ProjectRevista Panamericana de Salud Pública, 1997
- Salivary IgG subclasses in individuals with and without homozygous IGHG gene deletionsImmunology, 1996
- Salivary cortisol in psychoneuroendocrine research: Recent developments and applicationsPsychoneuroendocrinology, 1994
- Immunoglobulin levels in saliva in individuals with selective IgA deficiency: Compensatory IgM secretion and its correlation with HLA and susceptibility to infectionsJournal of Clinical Immunology, 1989
- Steroids in Saliva for Assessing Endocrine FunctionEndocrine Reviews, 1982